Many well-known large pharmaceutical companies, high-level changes!

There are also personnel changes in the top management of 3 well-known pharmaceutical companies! The vice president of Jingxin Pharmaceutical, the chairman of Huatong Pharmaceutical and some directors have resigned one after another.

75em; text-indent: 2em;">Vice President of Jingxin Pharmaceuticals resigns

75em; text-indent: 2em;">On October 9, Zhejiang Jingxin Pharmaceutical Co.

, Ltd.

75em; text-indent: 2em;">Huatong Pharmaceutical's chairman and some directors resign

75em; text-indent: 2em;">According to Huatong Pharmaceutical's announcement, the company recently received written resignation reports from Chairman Wang Luping, Director Jin Ding, Director Liu Wenqi, Chairman of the Board of Supervisors Zhang Quan, and Supervisor Yu Qunjian.
Among them, Wang Luping applied to resign from the position of chairman of the company and convener of the strategy committee due to work adjustments.
After resignation, Wang Luping no longer holds any position in the company;

75em; text-indent: 2em;">Jinding applied to resign as a director of the company due to work adjustments.
After resignation, Jinding still serves as the secretary of the company's board of directors;

75em; text-indent: 2em;">Liu Wenqi applied to resign as a director and member of the audit committee of the company due to work adjustments.
After resignation, Liu Wenqi's position in the company will be arranged separately;

75em; text-indent: 2em;">Zhang Quan applied to resign from the position of chairman of the company's board of supervisors due to work adjustments.
After resignation, Zhang Quan no longer holds any position in the company;

75em; text-indent: 2em;">Yu Qunjian applied to resign as a supervisor of the company due to work adjustments.
After resignation, Yu Qunjian still served as the head of the company's audit department.

75em; text-indent: 2em;">Merck CEO, Executive Vice President and Director of R&D Labs will change coaches

75em; text-indent: 2em;">According to media reports, recently, German Merck decided to promote Belén Garijo, a veteran of the company, to the position of Chief Executive Officer (CEO).
This is the first female CEO in Merck’s 352-year history.
She will start a new CEO in May 2021.
At that time, the current chairman and CEO of Merck’s global executive board, Stefan Oschmann, will step down as planned.

75em; text-indent: 2em;">Belén Garijo graduated from the University of Alcala in Spain with a degree in clinical pharmacology in 1989 and obtained a doctorate in medicine.
He was the senior vice president of Sanofi-Aventis’s global operations in Europe, the head of Genzyme’s global integration, and the biopharmaceutical business of Merck Chief Operating Officer (COO) of Merck Serono, Chief Executive Officer of Merck Healthcare, Vice Chairman of the Executive Board and Deputy Chief Executive Officer.

75em; text-indent: 2em;">In addition, Merck also announced that Dr.
Roger M.
Perlmutter, Executive Vice President and Director of Merck Research Laboratories (MRL), will retire next year.
Dr.
Dean Y.
Li will take over the position, and the appointment will take effect on January 1, 2021.

75em; text-indent: 2em;">Dr.
Dean Li graduated from the University of Washington School of Medicine and previously worked at the University of Utah.
His main research direction is translational medicine.
While teaching at the University of Utah, Dean Li co-founded a number of biotechnology companies based on the research work in his laboratory, including Recursion Pharmaceuticals, Hydra Biosciences, and Navigen Pharmaceuticals.
Dr.
Dean Li joined Merck in 2017 and is currently the Senior Associate Director of MRL, mainly responsible for discovery science and translational medicine.

75em; text-indent: 2em;">In addition to the above-mentioned companies, according to incomplete statistics from the People's Daily Health Client, 26 pharmaceutical companies issued notices of personnel changes in September.
Reasons for resignation include work reasons, personal reasons, and adjustments in the division of work.

75em; text-indent: 2em;">Northeast Pharmaceutical: Chairman resigns

75em; text-indent: 2em;">On September 30, Northeast Pharmaceutical issued an announcement stating that due to job changes, Mr.
Wei Haijun had applied for resignation from the company's eighth board of directors, director, chairman of the strategy committee, and member of the nomination committee.
After Mr.
Wei Haijun resigned, he did not hold any administrative positions in the company.

75em; text-indent: 2em;">Guangdong Tai'antang Pharmaceutical: Resignation of Director

75em; text-indent: 2em;">On September 30, Guangdong Tai'antang Pharmaceutical issued an announcement that Mr.
Chen Ji applied to resign from the position of director of the company's fifth board of directors due to personal reasons.
After his resignation, Mr.
Chen Ji no longer held any position in the company, and his resignation report was delivered to the board of directors.
Effective from date.

75em; text-indent: 2em;">Huisheng Bio: Deputy General Manager resigns

75em; text-indent: 2em;">On September 30, Wuhan Huisheng Biotechnology issued an announcement that Mr.
Wang Tianhui resigned from the position of Deputy General Manager and Secretary of the Board of Directors due to personal reasons, and his resignation report became effective from the date of delivery to the company’s board of directors.
After resignation, Mr.
Wang Tianhui no longer holds any position in the company.
Before appointing a new secretary of the board of directors, the chief financial officer Mr.
Yang Kaijie will temporarily perform the duties of secretary of the board of directors.

75em; text-indent: 2em;">Merck: Executive Director of Human Resources Business Partners resigns

75em; text-indent: 2em;">On September 25, MSD reported that Wang Zhen, the executive director of MSD China’s current human resources business partners, decided to leave the company to seek external development opportunities.
Beth Perrone, MSD’s senior vice president and head of HR business partners of the Human Health Business Department, and MSD’s global senior Vice President and President of Merck & Co.
China Luo Wanli jointly announced the news to employees.
Wang Zhen's last working day at Merck & Co.
, Ltd.
is October 16.

75em; text-indent: 2em;">GlaxoSmithKline: Resignation of Head of Respiratory Business Department in Southern China

75em; text-indent: 2em;">On September 25, GlaxoSmithKline announced that Lin Ziming, the head of the South China region of the Respiratory Business Department, decided to leave GSK due to personal reasons.
The last working day is October 31.

75em; text-indent: 2em;">Yuandong Biology: Independent director resigns

75em; text-indent: 2em;">On September 25, Chengdu Yuandong Biotechnology issued an announcement that Ms.
Zhang Hui, due to personal reasons, applied to resign from the position of independent director of the company's second board of directors, and at the same time resigned from the company's board of directors audit committee chairman and remuneration and appraisal committee member.
After resigning the above positions, Ms.
Zhang Hui no longer holds any position in the company.

75em; text-indent: 2em;">Sansheng Guojian: Senior management resigns

75em; text-indent: 2em;">On September 24, Sansheng Guojian issued an announcement that Mr.
Ni Hua applied for resignation from the position of deputy general manager of the company due to personal reasons.
Mr.
Ni Hua ceased to serve as the deputy general manager of the company from September 24, 2020.
After resignation, Mr.
Ni Hua will no longer hold any position in the company.

75em; text-indent: 2em;">Betta Pharmaceuticals: Change of Secretary of the Board of Directors

75em; text-indent: 2em;">On September 24, Betta Pharmaceuticals issued an announcement that Ms.
Tong Jia proposed to resign from the company's board secretary due to job adjustments and continue to serve as the chief executive officer.
According to relevant regulations, Ms.
Tong Jia's resignation report will take effect from the date of delivery to the company's board of directors.

75em; text-indent: 2em;">Taiwei Pharmaceutical: Resignation of Director

75em; text-indent: 2em;">On September 23, Taiwei Pharmaceutical issued an announcement stating that Mr.
Wang Jifeng had applied for resignation from the position of director and financial officer of the company due to personal reasons.
His resignation will take effect on September 21, 2020.

75em; text-indent: 2em;">Bio Valley: Director resigns

75em; text-indent: 2em;">On September 23, Yunnan Bio Valley Pharmaceutical announced that Mr.
Zhan Yuliang had resigned due to personal reasons and resigned from the position of director of the company.
The resignation will take effect on September 21, 2020.
Mr.
Zhan Yuliang no longer holds other positions in the company after his resignation.

75em; text-indent: 2em;">Haiguang Pharmaceutical: Resignation of Director

75em; text-indent: 2em;">On September 22, Tianjin Haiguang Pharmaceutical issued an announcement stating that the company’s board of directors received a resignation report from Director Di Yanpeng on September 18, 2020.
Mr.
Di Yanpeng resigned as a director of the company due to work adjustments.
Then take up other positions in the company.

75em; text-indent: 2em;">Harbin Pharmaceutical Group: Deputy General Manager resigns

75em; text-indent: 2em;">On September 21, Harbin Pharmaceutical Group Co.
, Ltd.
issued an announcement that due to personal reasons, Mr.
Pan Hong resigned from the position of deputy general manager of the company.
After resignation, Mr.
Pan Hong will serve as the company's senior consultant.

75em; text-indent: 2em;">Cap Bio: Director resigns

75em; text-indent: 2em;">On September 21, Guangdong Kaipu Biotechnology Co.
, Ltd.
issued an announcement stating that Mr.
Cai Danping had applied for resignation from the position of director of the fourth board of directors and member of the strategy committee of the company due to personal reasons.
After resignation, Mr.
Cai Danping will not hold any position in the company.

75em; text-indent: 2em;">Fengyuan Pharmaceutical: Deputy General Manager resigns

75em; text-indent: 2em;">On September 17, Anhui Fengyuan Pharmaceutical announced that Ms.
Zhu Xiaoqing would resign from the position of deputy general manager of the company due to work transfer.
The resignation report shall take effect from the day it is delivered to the company's board of directors.
Ms.
Zhu Xiaoqing will not hold any position in the company and its holding subsidiaries after resigning from the position of deputy general manager of the company.
On the same day, the 8th (temporary) meeting of the 8th Board of Directors was held and Lu Zhenhong was appointed as the deputy general manager of the company.

75em; text-indent: 2em;">Litai Health: Director resigns

75em; text-indent: 2em;">On September 15, Guangdong Litai Health Industry Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a resignation report from Ms.
Du Danhong on September 11, 2020.
Ms.
Du Danhong resigned from the position of director and general manager of the company due to personal reasons.
The resignation shall take effect from the day when the new director is elected by the general meeting of shareholders.
The above-mentioned resignees will no longer hold other positions in the company after resignation.

75em; text-indent: 2em;">Hairong Pharmaceutical: Director resigns

75em; text-indent: 2em;">On September 14, Nanjing Hairong Pharmaceutical Technology Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a resignation report from Mr.
Jiang Yimin on September 10, 2020.
He resigned from the position of director and financial officer of the company due to personal reasons.
No longer hold other positions in the company.

75em; text-indent: 2em;">Huaren Pharmaceutical: Senior management resigns

75em; text-indent: 2em;">On September 7, Huaren Pharmaceutical issued an announcement stating that Ms.
Wang Wenping had applied to resign from the position of Senior Vice President and Chief Financial Officer due to personal reasons, and would no longer continue to hold other positions in the company after resignation.
His application for resignation shall take effect from the date of delivery to the board of directors.
In addition, prior to the appointment of the chief financial officer, the company’s board of directors appointed Mr.
Yang Xiaodong, the chairman of the board, to perform the duties of chief financial officer temporarily.

75em; text-indent: 2em;">Ruibang Pharmaceutical: Resignation of Supervisors and Directors

75em; text-indent: 2em;">On September 7, Zhejiang Ruibang Pharmaceutical issued two announcements on the resignation of senior executives.
Ms.
Huang Yaping voluntarily resigned from the company's supervisory position due to work reasons.
Ms.
Sun Yan voluntarily resigned as a director of the company due to work reasons.
The two resignation reports are effective from September 4, 2020.
The above-mentioned resignees will no longer hold other positions in the company after resignation.

75em; text-indent: 2em;">Novartis China: President leaves office

75em; text-indent: 2em;">On the afternoon of September 4, Novartis announced to employees that Yin Xudong, president of Novartis Pharmaceuticals Asia Pacific, Middle East and Africa (APMA) and Novartis Group China President, had decided to leave Novartis due to personal reasons.
After Yin Xudong leaves, Dan Brindle will take over as President of Novartis China, and Iris Zemzoum will take over as President of Asia Pacific, Middle East and Africa (APMA).

75em; text-indent: 2em;">SINBON Pharmaceuticals: Resignation of Director

75em; text-indent: 2em;">Recently, Guizhou Xinbang Pharmaceutical announced that the board of directors received written resignation reports from the company’s directors, Mr.
Zhang Jieqing and Mr.
Ma Sheng, on September 4.
Mr.
Zhang Jieqing and Mr.
Ma Sheng applied to resign from the company's directorships due to personal work reasons.
After Mr.
Zhang Jieqing resigned as a director, he still served as the deputy general manager of the company; after Mr.
Ma Sheng resigned as a director, he still served in the company's subsidiaries.
The resignation reports of the two men took effect when they were delivered to the company's board of directors.

75em; text-indent: 2em;">Datang Pharmaceutical: Senior management resigns

75em; text-indent: 2em;">On September 4, Inner Mongolia Datang Pharmaceutical issued an announcement stating that the board of directors of the company received a resignation report from Deputy General Manager Yu Haiquan on September 3, 2020.
Due to personal reasons, Mr.
Yu Haiquan applied to resign from the position of Deputy General Manager of the company.
Continue to hold other positions in the company after resignation.

75em; text-indent: 2em;">Borui Bio: Resignation on behalf of the supervisor

75em; text-indent: 2em;">On September 2, Borui Biomedical (Suzhou) Co.
, Ltd.
issued an announcement stating that on August 31, 2020, the company's board of supervisors received written resignation reports from Mr.
Huang Yangqing and Ms.
Zhang Li, the employee representative supervisors of the company's second board of supervisors.
Due to personal reasons, Mr.
Huang Yangqing and Ms.
Zhang Li applied to the Board of Supervisors to resign as the employee representative supervisor of the company's second session of the Board of Supervisors.
After their resignation, Mr.
Huang Yangqing and Ms.
Zhang Li will continue to serve in the company.

75em; text-indent: 2em;">Zhongzhu Medical: Resignation of Director

75em; text-indent: 2em;">On September 2, Zhongzhu Medical Holdings Co.
, Ltd.
issued an announcement stating that Mr.
Zhang Minghua had resigned from the position of director of the company's ninth board of directors and member of the remuneration and assessment committee of the board of directors due to personal reasons.

75em; text-indent: 2em;">Moyao Pharmaceutical: Resignation of Supervisor

75em; text-indent: 2em;">On September 2, Anhui Moyao Pharmaceutical issued an announcement stating that the company’s board of supervisors received a resignation report from the chairman of the board of supervisors, Mr.
Xu Huibiao, on August 31, 2020.
Mr.
Xu Huibiao requested to resign as chairman of the board of supervisors due to personal reasons.
Position.
After resignation, he no longer holds other positions in the company.

75em; text-indent: 2em;">Lixin Pharmaceutical: Deputy General Manager resigns

75em; text-indent: 2em;">On September 1, Henan Lixin Pharmaceutical issued an announcement stating that Qin Wei and Wang Zhongmin resigned from the positions of deputy general managers due to the adjustment of the company's internal positions, and will no longer hold other positions in the company after resignation.

75em; text-indent: 2em;">Changshan Pharmaceutical: Deputy General Manager resigns

75em; text-indent: 2em;">On September 1, Hebei Changshan Biochemical Pharmaceuticals issued an announcement that Mr.
Qi Yining applied for resignation from the company's deputy general manager due to personal reasons.
The application for resignation shall take effect from the date when the resignation report is delivered to the company's board of directors.
After Mr.
Qi Yining resigns, he will no longer hold any position in the company.

75em; text-indent: 2em;">Vice President of Jingxin Pharmaceuticals resigns

Vice President of Jingxin Pharmaceuticals resigns

75em; text-indent: 2em;">On October 9, Zhejiang Jingxin Pharmaceutical Co.

, Ltd.
announced the resignation of the company's vice president.
The announcement stated that the company’s board of directors received a written resignation report from Mr.

On October 9, Zhejiang Jingxin Pharmaceutical Co.

Huatong Pharmaceutical's chairman and some directors resign

75em; text-indent: 2em;">According to Huatong Pharmaceutical's announcement, the company recently received written resignation reports from Chairman Wang Luping, Director Jin Ding, Director Liu Wenqi, Chairman of the Board of Supervisors Zhang Quan, and Supervisor Yu Qunjian.

According to Huatong Pharmaceutical's announcement, the company recently received written resignation reports from Chairman Wang Luping, Director Jin Ding, Director Liu Wenqi, Chairman of the Board of Supervisors Zhang Quan, and Supervisor Yu Qunjian.

Jinding applied to resign as a director of the company due to work adjustments.

Liu Wenqi applied to resign as a director and member of the audit committee of the company due to work adjustments.

Zhang Quan applied to resign from the position of chairman of the company's board of supervisors due to work adjustments.

Yu Qunjian applied to resign as a supervisor of the company due to work adjustments.

Merck CEO, Executive Vice President and Director of R&D Labs will change coaches

75em; text-indent: 2em;">According to media reports, recently, German Merck decided to promote Belén Garijo, a veteran of the company, to the position of Chief Executive Officer (CEO).

According to media reports, recently, German Merck decided to promote Belén Garijo, a veteran of the company, to the position of Chief Executive Officer (CEO).

Belén Garijo graduated from the University of Alcala in Spain with a degree in clinical pharmacology in 1989 and obtained a doctorate in medicine.

In addition, Merck also announced that Dr.

Dr.
Dean Li graduated from the University of Washington School of Medicine and previously worked at the University of Utah.
His main research direction is translational medicine.
While teaching at the University of Utah, Dean Li co-founded a number of biotechnology companies based on the research work in his laboratory, including Recursion Pharmaceuticals, Hydra Biosciences, and Navigen Pharmaceuticals.
Dr.
Dean Li joined Merck in 2017 and is currently the Senior Associate Director of MRL, mainly responsible for discovery science and translational medicine.

75em; text-indent: 2em;">In addition to the above-mentioned companies, according to incomplete statistics from the People's Daily Health Client, 26 pharmaceutical companies issued notices of personnel changes in September.
Reasons for resignation include work reasons, personal reasons, and adjustments in the division of work.

In addition to the above-mentioned companies, according to incomplete statistics from the People's Daily Health Client, 26 pharmaceutical companies issued notices of personnel changes in September.
Reasons for resignation include work reasons, personal reasons, and adjustments in the division of work.

75em; text-indent: 2em;">Northeast Pharmaceutical: Chairman resigns

Northeast Pharmaceutical: Chairman resigns

75em; text-indent: 2em;">On September 30, Northeast Pharmaceutical issued an announcement stating that due to job changes, Mr.
Wei Haijun had applied for resignation from the company's eighth board of directors, director, chairman of the strategy committee, and member of the nomination committee.
After Mr.
Wei Haijun resigned, he did not hold any administrative positions in the company.

On September 30, Northeast Pharmaceutical issued an announcement stating that due to job changes, Mr.
Wei Haijun had applied for resignation from the company's eighth board of directors, director, chairman of the strategy committee, and member of the nomination committee.
After Mr.
Wei Haijun resigned, he did not hold any administrative positions in the company.

75em; text-indent: 2em;">Guangdong Tai'antang Pharmaceutical: Resignation of Director

Guangdong Tai'antang Pharmaceutical: Resignation of Director

75em; text-indent: 2em;">On September 30, Guangdong Tai'antang Pharmaceutical issued an announcement that Mr.
Chen Ji applied to resign from the position of director of the company's fifth board of directors due to personal reasons.
After his resignation, Mr.
Chen Ji no longer held any position in the company, and his resignation report was delivered to the board of directors.
Effective from date.

On September 30, Guangdong Tai'antang Pharmaceutical issued an announcement that Mr.
Chen Ji applied to resign from the position of director of the company's fifth board of directors due to personal reasons.
After his resignation, Mr.
Chen Ji no longer held any position in the company, and his resignation report was delivered to the board of directors.
Effective from date.

75em; text-indent: 2em;">Huisheng Bio: Deputy General Manager resigns

Huisheng Bio: Deputy General Manager resigns

75em; text-indent: 2em;">On September 30, Wuhan Huisheng Biotechnology issued an announcement that Mr.
Wang Tianhui resigned from the position of Deputy General Manager and Secretary of the Board of Directors due to personal reasons, and his resignation report became effective from the date of delivery to the company’s board of directors.
After resignation, Mr.
Wang Tianhui no longer holds any position in the company.
Before appointing a new secretary of the board of directors, the chief financial officer Mr.
Yang Kaijie will temporarily perform the duties of secretary of the board of directors.

On September 30, Wuhan Huisheng Biotechnology issued an announcement that Mr.
Wang Tianhui resigned from the position of Deputy General Manager and Secretary of the Board of Directors due to personal reasons, and his resignation report became effective from the date of delivery to the company’s board of directors.
After resignation, Mr.
Wang Tianhui no longer holds any position in the company.
Before appointing a new secretary of the board of directors, the chief financial officer Mr.
Yang Kaijie will temporarily perform the duties of secretary of the board of directors.

75em; text-indent: 2em;">Merck: Executive Director of Human Resources Business Partners resigns

Merck: Executive Director of Human Resources Business Partners resigns

75em; text-indent: 2em;">On September 25, MSD reported that Wang Zhen, the executive director of MSD China’s current human resources business partners, decided to leave the company to seek external development opportunities.
Beth Perrone, MSD’s senior vice president and head of HR business partners of the Human Health Business Department, and MSD’s global senior Vice President and President of Merck & Co.
China Luo Wanli jointly announced the news to employees.
Wang Zhen's last working day at Merck & Co.
, Ltd.
is October 16.

On September 25, MSD reported that Wang Zhen, the executive director of MSD China’s current human resources business partners, decided to leave the company to seek external development opportunities.
Beth Perrone, MSD’s senior vice president and head of HR business partners of the Human Health Business Department, and MSD’s global senior Vice President and President of Merck & Co.
China Luo Wanli jointly announced the news to employees.
Wang Zhen's last working day at Merck & Co.
, Ltd.
is October 16.

75em; text-indent: 2em;">GlaxoSmithKline: Resignation of Head of Respiratory Business Department in Southern China

GlaxoSmithKline: Resignation of Head of Respiratory Business Department in Southern China

75em; text-indent: 2em;">On September 25, GlaxoSmithKline announced that Lin Ziming, the head of the South China region of the Respiratory Business Department, decided to leave GSK due to personal reasons.
The last working day is October 31.

On September 25, GlaxoSmithKline announced that Lin Ziming, the head of the South China region of the Respiratory Business Department, decided to leave GSK due to personal reasons.
The last working day is October 31.

75em; text-indent: 2em;">Yuandong Biology: Independent director resigns

Yuandong Biology: Independent director resigns

75em; text-indent: 2em;">On September 25, Chengdu Yuandong Biotechnology issued an announcement that Ms.
Zhang Hui, due to personal reasons, applied to resign from the position of independent director of the company's second board of directors, and at the same time resigned from the company's board of directors audit committee chairman and remuneration and appraisal committee member.
After resigning the above positions, Ms.
Zhang Hui no longer holds any position in the company.

On September 25, Chengdu Yuandong Biotechnology issued an announcement that Ms.
Zhang Hui, due to personal reasons, applied to resign from the position of independent director of the company's second board of directors, and at the same time resigned from the company's board of directors audit committee chairman and remuneration and appraisal committee member.
After resigning the above positions, Ms.
Zhang Hui no longer holds any position in the company.

75em; text-indent: 2em;">Sansheng Guojian: Senior management resigns

Sansheng Guojian: Senior management resigns

75em; text-indent: 2em;">On September 24, Sansheng Guojian issued an announcement that Mr.
Ni Hua applied for resignation from the position of deputy general manager of the company due to personal reasons.
Mr.
Ni Hua ceased to serve as the deputy general manager of the company from September 24, 2020.
After resignation, Mr.
Ni Hua will no longer hold any position in the company.

On September 24, Sansheng Guojian issued an announcement that Mr.
Ni Hua applied for resignation from the position of deputy general manager of the company due to personal reasons.
Mr.
Ni Hua ceased to serve as the deputy general manager of the company from September 24, 2020.
After resignation, Mr.
Ni Hua will no longer hold any position in the company.

75em; text-indent: 2em;">Betta Pharmaceuticals: Change of Secretary of the Board of Directors

Betta Pharmaceuticals: Change of Secretary of the Board of Directors

75em; text-indent: 2em;">On September 24, Betta Pharmaceuticals issued an announcement that Ms.
Tong Jia proposed to resign from the company's board secretary due to job adjustments and continue to serve as the chief executive officer.
According to relevant regulations, Ms.
Tong Jia's resignation report will take effect from the date of delivery to the company's board of directors.

On September 24, Betta Pharmaceuticals issued an announcement that Ms.
Tong Jia proposed to resign from the company's board secretary due to job adjustments and continue to serve as the chief executive officer.
According to relevant regulations, Ms.
Tong Jia's resignation report will take effect from the date of delivery to the company's board of directors.

75em; text-indent: 2em;">Taiwei Pharmaceutical: Resignation of Director

Taiwei Pharmaceutical: Resignation of Director

75em; text-indent: 2em;">On September 23, Taiwei Pharmaceutical issued an announcement stating that Mr.
Wang Jifeng had applied for resignation from the position of director and financial officer of the company due to personal reasons.
His resignation will take effect on September 21, 2020.

On September 23, Taiwei Pharmaceutical issued an announcement stating that Mr.
Wang Jifeng had applied for resignation from the position of director and financial officer of the company due to personal reasons.
His resignation will take effect on September 21, 2020.

75em; text-indent: 2em;">Bio Valley: Director resigns

Bio Valley: Director resigns

75em; text-indent: 2em;">On September 23, Yunnan Bio Valley Pharmaceutical announced that Mr.
Zhan Yuliang had resigned due to personal reasons and resigned from the position of director of the company.
The resignation will take effect on September 21, 2020.
Mr.
Zhan Yuliang no longer holds other positions in the company after his resignation.

On September 23, Yunnan Bio Valley Pharmaceutical announced that Mr.
Zhan Yuliang had resigned due to personal reasons and resigned from the position of director of the company.
The resignation will take effect on September 21, 2020.
Mr.
Zhan Yuliang no longer holds other positions in the company after his resignation.

75em; text-indent: 2em;">Haiguang Pharmaceutical: Resignation of Director

Haiguang Pharmaceutical: Resignation of Director

75em; text-indent: 2em;">On September 22, Tianjin Haiguang Pharmaceutical issued an announcement stating that the company’s board of directors received a resignation report from Director Di Yanpeng on September 18, 2020.
Mr.
Di Yanpeng resigned as a director of the company due to work adjustments.
Then take up other positions in the company.

On September 22, Tianjin Haiguang Pharmaceutical issued an announcement stating that the company’s board of directors received a resignation report from Director Di Yanpeng on September 18, 2020.
Mr.
Di Yanpeng resigned as a director of the company due to work adjustments.
Then take up other positions in the company.

75em; text-indent: 2em;">Harbin Pharmaceutical Group: Deputy General Manager resigns

Harbin Pharmaceutical Group: Deputy General Manager resigns

75em; text-indent: 2em;">On September 21, Harbin Pharmaceutical Group Co.
, Ltd.
issued an announcement that due to personal reasons, Mr.
Pan Hong resigned from the position of deputy general manager of the company.
After resignation, Mr.
Pan Hong will serve as the company's senior consultant.

On September 21, Harbin Pharmaceutical Group Co.
, Ltd.
issued an announcement that due to personal reasons, Mr.
Pan Hong resigned from the position of deputy general manager of the company.
After resignation, Mr.
Pan Hong will serve as the company's senior consultant.

75em; text-indent: 2em;">Cap Bio: Director resigns

Cap Bio: Director resigns

75em; text-indent: 2em;">On September 21, Guangdong Kaipu Biotechnology Co.
, Ltd.
issued an announcement stating that Mr.
Cai Danping had applied for resignation from the position of director of the fourth board of directors and member of the strategy committee of the company due to personal reasons.
After resignation, Mr.
Cai Danping will not hold any position in the company.

On September 21, Guangdong Kaipu Biotechnology Co.
, Ltd.
issued an announcement stating that Mr.
Cai Danping had applied for resignation from the position of director of the fourth board of directors and member of the strategy committee of the company due to personal reasons.
After resignation, Mr.
Cai Danping will not hold any position in the company.

75em; text-indent: 2em;">Fengyuan Pharmaceutical: Deputy General Manager resigns

Fengyuan Pharmaceutical: Deputy General Manager resigns

75em; text-indent: 2em;">On September 17, Anhui Fengyuan Pharmaceutical announced that Ms.
Zhu Xiaoqing would resign from the position of deputy general manager of the company due to work transfer.
The resignation report shall take effect from the day it is delivered to the company's board of directors.
Ms.
Zhu Xiaoqing will not hold any position in the company and its holding subsidiaries after resigning from the position of deputy general manager of the company.
On the same day, the 8th (temporary) meeting of the 8th Board of Directors was held and Lu Zhenhong was appointed as the deputy general manager of the company.

On September 17, Anhui Fengyuan Pharmaceutical announced that Ms.
Zhu Xiaoqing would resign from the position of deputy general manager of the company due to work transfer.
The resignation report shall take effect from the day it is delivered to the company's board of directors.
Ms.
Zhu Xiaoqing will not hold any position in the company and its holding subsidiaries after resigning from the position of deputy general manager of the company.
On the same day, the 8th (temporary) meeting of the 8th Board of Directors was held and Lu Zhenhong was appointed as the deputy general manager of the company.

75em; text-indent: 2em;">Litai Health: Director resigns

Litai Health: Director resigns

75em; text-indent: 2em;">On September 15, Guangdong Litai Health Industry Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a resignation report from Ms.
Du Danhong on September 11, 2020.
Ms.
Du Danhong resigned from the position of director and general manager of the company due to personal reasons.
The resignation shall take effect from the day when the new director is elected by the general meeting of shareholders.
The above-mentioned resignees will no longer hold other positions in the company after resignation.

On September 15, Guangdong Litai Health Industry Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a resignation report from Ms.
Du Danhong on September 11, 2020.
Ms.
Du Danhong resigned from the position of director and general manager of the company due to personal reasons.
The resignation shall take effect from the day when the new director is elected by the general meeting of shareholders.
The above-mentioned resignees will no longer hold other positions in the company after resignation.

75em; text-indent: 2em;">Hairong Pharmaceutical: Director resigns

Hairong Pharmaceutical: Director resigns

75em; text-indent: 2em;">On September 14, Nanjing Hairong Pharmaceutical Technology Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a resignation report from Mr.
Jiang Yimin on September 10, 2020.
He resigned from the position of director and financial officer of the company due to personal reasons.
No longer hold other positions in the company.

On September 14, Nanjing Hairong Pharmaceutical Technology Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a resignation report from Mr.
Jiang Yimin on September 10, 2020.
He resigned from the position of director and financial officer of the company due to personal reasons.
No longer hold other positions in the company.

75em; text-indent: 2em;">Huaren Pharmaceutical: Senior management resigns

Huaren Pharmaceutical: Senior management resigns

75em; text-indent: 2em;">On September 7, Huaren Pharmaceutical issued an announcement stating that Ms.
Wang Wenping had applied to resign from the position of Senior Vice President and Chief Financial Officer due to personal reasons, and would no longer continue to hold other positions in the company after resignation.
His application for resignation shall take effect from the date of delivery to the board of directors.
In addition, prior to the appointment of the chief financial officer, the company’s board of directors appointed Mr.
Yang Xiaodong, the chairman of the board, to perform the duties of chief financial officer temporarily.

On September 7, Huaren Pharmaceutical issued an announcement stating that Ms.
Wang Wenping had applied to resign from the position of Senior Vice President and Chief Financial Officer due to personal reasons, and would no longer continue to hold other positions in the company after resignation.
His application for resignation shall take effect from the date of delivery to the board of directors.
In addition, prior to the appointment of the chief financial officer, the company’s board of directors appointed Mr.
Yang Xiaodong, the chairman of the board, to perform the duties of chief financial officer temporarily.

75em; text-indent: 2em;">Ruibang Pharmaceutical: Resignation of Supervisors and Directors

Ruibang Pharmaceutical: Resignation of Supervisors and Directors

75em; text-indent: 2em;">On September 7, Zhejiang Ruibang Pharmaceutical issued two announcements on the resignation of senior executives.
Ms.
Huang Yaping voluntarily resigned from the company's supervisory position due to work reasons.
Ms.
Sun Yan voluntarily resigned as a director of the company due to work reasons.
The two resignation reports are effective from September 4, 2020.
The above-mentioned resignees will no longer hold other positions in the company after resignation.

On September 7, Zhejiang Ruibang Pharmaceutical issued two announcements on the resignation of senior executives.
Ms.
Huang Yaping voluntarily resigned from the company's supervisory position due to work reasons.
Ms.
Sun Yan voluntarily resigned as a director of the company due to work reasons.
The two resignation reports are effective from September 4, 2020.
The above-mentioned resignees will no longer hold other positions in the company after resignation.

75em; text-indent: 2em;">Novartis China: President leaves office

Novartis China: President leaves office

75em; text-indent: 2em;">On the afternoon of September 4, Novartis announced to employees that Yin Xudong, president of Novartis Pharmaceuticals Asia Pacific, Middle East and Africa (APMA) and Novartis Group China President, had decided to leave Novartis due to personal reasons.
After Yin Xudong leaves, Dan Brindle will take over as President of Novartis China, and Iris Zemzoum will take over as President of Asia Pacific, Middle East and Africa (APMA).

On the afternoon of September 4, Novartis announced to employees that Yin Xudong, president of Novartis Pharmaceuticals Asia Pacific, Middle East and Africa (APMA) and Novartis Group China President, had decided to leave Novartis due to personal reasons.
After Yin Xudong leaves, Dan Brindle will take over as President of Novartis China, and Iris Zemzoum will take over as President of Asia Pacific, Middle East and Africa (APMA).

75em; text-indent: 2em;">SINBON Pharmaceuticals: Resignation of Director

SINBON Pharmaceuticals: Resignation of Director

75em; text-indent: 2em;">Recently, Guizhou Xinbang Pharmaceutical announced that the board of directors received written resignation reports from the company’s directors, Mr.
Zhang Jieqing and Mr.
Ma Sheng, on September 4.
Mr.
Zhang Jieqing and Mr.
Ma Sheng applied to resign from the company's directorships due to personal work reasons.
After Mr.
Zhang Jieqing resigned as a director, he still served as the deputy general manager of the company; after Mr.
Ma Sheng resigned as a director, he still served in the company's subsidiaries.
The resignation reports of the two men took effect when they were delivered to the company's board of directors.

Recently, Guizhou Xinbang Pharmaceutical announced that the board of directors received written resignation reports from the company’s directors, Mr.
Zhang Jieqing and Mr.
Ma Sheng, on September 4.
Mr.
Zhang Jieqing and Mr.
Ma Sheng applied to resign from the company's directorships due to personal work reasons.
After Mr.
Zhang Jieqing resigned as a director, he still served as the deputy general manager of the company; after Mr.
Ma Sheng resigned as a director, he still served in the company's subsidiaries.
The resignation reports of the two men took effect when they were delivered to the company's board of directors.

75em; text-indent: 2em;">Datang Pharmaceutical: Senior management resigns

Datang Pharmaceutical: Senior management resigns

75em; text-indent: 2em;">On September 4, Inner Mongolia Datang Pharmaceutical issued an announcement stating that the board of directors of the company received a resignation report from Deputy General Manager Yu Haiquan on September 3, 2020.
Due to personal reasons, Mr.
Yu Haiquan applied to resign from the position of Deputy General Manager of the company.
Continue to hold other positions in the company after resignation.

On September 4, Inner Mongolia Datang Pharmaceutical issued an announcement stating that the board of directors of the company received a resignation report from Deputy General Manager Yu Haiquan on September 3, 2020.
Due to personal reasons, Mr.
Yu Haiquan applied to resign from the position of Deputy General Manager of the company.
Continue to hold other positions in the company after resignation.

75em; text-indent: 2em;">Borui Bio: Resignation on behalf of the supervisor

Borui Bio: Resignation on behalf of the supervisor

75em; text-indent: 2em;">On September 2, Borui Biomedical (Suzhou) Co.
, Ltd.
issued an announcement stating that on August 31, 2020, the company's board of supervisors received written resignation reports from Mr.
Huang Yangqing and Ms.
Zhang Li, the employee representative supervisors of the company's second board of supervisors.
Due to personal reasons, Mr.
Huang Yangqing and Ms.
Zhang Li applied to the Board of Supervisors to resign as the employee representative supervisor of the company's second session of the Board of Supervisors.
After their resignation, Mr.
Huang Yangqing and Ms.
Zhang Li will continue to serve in the company.

On September 2, Borui Biomedical (Suzhou) Co.
, Ltd.
issued an announcement stating that on August 31, 2020, the company's board of supervisors received written resignation reports from Mr.
Huang Yangqing and Ms.
Zhang Li, the employee representative supervisors of the company's second board of supervisors.
Due to personal reasons, Mr.
Huang Yangqing and Ms.
Zhang Li applied to the Board of Supervisors to resign as the employee representative supervisor of the company's second session of the Board of Supervisors.
After their resignation, Mr.
Huang Yangqing and Ms.
Zhang Li will continue to serve in the company.

75em; text-indent: 2em;">Zhongzhu Medical: Resignation of Director

Zhongzhu Medical: Resignation of Director

75em; text-indent: 2em;">On September 2, Zhongzhu Medical Holdings Co.
, Ltd.
issued an announcement stating that Mr.
Zhang Minghua had resigned from the position of director of the company's ninth board of directors and member of the remuneration and assessment committee of the board of directors due to personal reasons.

On September 2, Zhongzhu Medical Holdings Co.
, Ltd.
issued an announcement stating that Mr.
Zhang Minghua had resigned from the position of director of the company's ninth board of directors and member of the remuneration and assessment committee of the board of directors due to personal reasons.

75em; text-indent: 2em;">Moyao Pharmaceutical: Resignation of Supervisor

Moyao Pharmaceutical: Resignation of Supervisor

75em; text-indent: 2em;">On September 2, Anhui Moyao Pharmaceutical issued an announcement stating that the company’s board of supervisors received a resignation report from the chairman of the board of supervisors, Mr.
Xu Huibiao, on August 31, 2020.
Mr.
Xu Huibiao requested to resign as chairman of the board of supervisors due to personal reasons.
Position.
After resignation, he no longer holds other positions in the company.

On September 2, Anhui Moyao Pharmaceutical issued an announcement stating that the company’s board of supervisors received a resignation report from the chairman of the board of supervisors, Mr.
Xu Huibiao, on August 31, 2020.
Mr.
Xu Huibiao requested to resign as chairman of the board of supervisors due to personal reasons.
Position.
After resignation, he no longer holds other positions in the company.

75em; text-indent: 2em;">Lixin Pharmaceutical: Deputy General Manager resigns

Lixin Pharmaceutical: Deputy General Manager resigns

75em; text-indent: 2em;">On September 1, Henan Lixin Pharmaceutical issued an announcement stating that Qin Wei and Wang Zhongmin resigned from the positions of deputy general managers due to the adjustment of the company's internal positions, and will no longer hold other positions in the company after resignation.

On September 1, Henan Lixin Pharmaceutical issued an announcement stating that Qin Wei and Wang Zhongmin resigned from the positions of deputy general managers due to the adjustment of the company's internal positions, and will no longer hold other positions in the company after resignation.

75em; text-indent: 2em;">Changshan Pharmaceutical: Deputy General Manager resigns

Changshan Pharmaceutical: Deputy General Manager resigns

75em; text-indent: 2em;">91，，。。，。

91，，。。，。